ERBB2 and aneurysmal bone cyst: Dalpiciclib (SHR6390) is a highly selective, small molecule CDK4/6 inhibitor, recently approved for HR-positive, HER2-negative ABC in China, based on impressive efficacy and manageable toxicity in a randomized phase 3 DAWNA‐1 trial8.